A pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma

Small cell carcinoma (SCC) or microcytic carcinoma of the urinary bladder is a rare entity comprising approximately 0.5% of all bladder tumors. Due to its rarity, no prospective studies evaluating the most effective treatment have been published in the medical literature. Several cases of bladder SCC have been presented so far. We describe our case report and we revise the recent literature. Our patient was diagnosed with pure bladder SCC and prostatic adenocarcinoma. After the initial and complete transurethral resection of the bladder tumour (TUR-BT), he underwent a thorax and mediastinum computer tomography (CT) examination to exclude primary pulmonary small cell carcinoma and a bone scan scintigraphy for staging purposes. He received a three 14-day cycles of Cisplatin-containing chemotherapeutic schema and a single dose of Luteinizing-Hormone Releasing hormone (LHRH) analogue injection after 14 days of bicalutamide administration. The patient is followed for 24 months without any signs of bladder SCC recurrence or biochemical or local relapse from prostatic adenocarcinoma

PlasmiR: A Manual Collection of Circulating microRNAs of Prognostic and Diagnostic Value

Simple Summary Only recently have the important biomarker capacities of microRNAs (miRNAs) in blood samples during disease been revealed. miRNAs are abundantly detected in circulation, and are less prone to degradation than longer RNA. Details regarding potential discriminatory miRNAs against numerous pathologic conditions are dispersed across articles, while existing resources that catalogue miRNA abundance in blood samples are not tailored to biomarker research. This study presents the meticulous manual curation of more than 200 articles that specifically interrogate the biomarker potential of miRNAs in whole blood, serum, or plasma. This annotation effort resulted in the creation of plasmiR, a database that systematically provides experimental evidence for the diagnostic and prognostic potential of circulating miRNAs against human diseases. plasmiR features 1021 entries, accompanied by rich study-specific meta-information, and an intuitive interface that enables the formation of complex queries and visualizations. Only recently, microRNAs (miRNAs) were found to exist in traceable and distinctive amounts in the human circulatory system, bringing forth the intriguing possibility of using them as minimally invasive biomarkers. miRNAs are short non-coding RNAs that act as potent post-transcriptional regulators of gene expression. Extensive studies in cancer and other disease landscapes investigate the protective/pathogenic functions of dysregulated miRNAs, as well as their biomarker potential. A specialized resource amassing experimentally verified, circulating miRNA biomarkers does not exist. We queried the existing literature to identify articles assessing diagnostic/prognostic roles of miRNAs in blood, serum, or plasma samples. Articles were scrutinized in order to exclude instances lacking sufficient experimental documentation or employing no biomarker assessment methods. We incorporated information from more than 200 biomedical articles, annotating crucial meta-information including cohort sizes, inclusion-exclusion criteria, disease/healthy confirmation methods and quantification details. miRNAs and diseases were systematically characterized using reference resources. Our circulating miRNA biomarker collection is provided as an online database, plasmiR. It consists of 1021 entries regarding 251 miRNAs and 112 diseases. More than half of plasmiR’s entries refer to cancerous and neoplastic conditions, 183 of them (32%) describing prognostic associations. plasmiR facilitates smart queries, emphasizing visualization and exploratory modes for all researchers